Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Puma BiotechnologyPBYI -3.03%53 Days Inventory is 62.19 as of Mar. 2026, which is 84% above its 10-year median of 33.79. GuruFocus rates PBYI with a GF Score™ of 53/100 and a GF Value™ of $3.34 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 638 Biotechnology companies, Puma Biotechnology ranks better than 85.58% on this metric.
The historical rank and industry rank for Puma Biotechnology's Days Inventory or its related term are showing as below:
PBYI'
s Days Inventory Range Over the Past 10 Years
Min: 24.53 Med: 33.79 Max: 132.91
Current: 51.61
During the past 13 years, Puma Biotechnology's highest Days Inventory was 132.91. The lowest was 24.53. And the median was 33.79.
PBYI's Days Inventory is ranked better than 85.58% of 638
companies
in the Biotechnology industry
Industry Median: 182.245
vs PBYI: 51.61
Puma Biotechnology's Days Inventory
declined
from Mar. 2025 (75.53) to Mar. 2026 (62.19).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Puma Biotechnology's Inventory Turnover for the
three
months ended in Mar. 2026 was 1.47.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Puma Biotechnology's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.16.
Puma Biotechnology (NAS:PBYI) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Puma Biotechnology's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Puma Biotechnology's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Puma Biotechnology Days Inventory Related Terms
Puma Biotechnology Days Inventory Historical Data
* Premium members only.
The historical data trend for Puma Biotechnology's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PBYI vs EVMN, OCGN, EDIT: Days Inventory Comparison
For the Biotechnology subindustry, Puma Biotechnology's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Puma Biotechnology Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Puma Biotechnology's Days Inventory distribution charts can be found below:
* The bar in red indicates where Puma Biotechnology's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Puma Biotechnology (PBYI) has a Days Inventory of 62.19 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Puma Biotechnology and its competitors. This is 84% above median its historical median of 33.79. Over the past decade, Puma Biotechnology's Days Inventory has ranged from 24.53 to 132.91. According to the industry distribution chart, Puma Biotechnology ranks #92 out of 638 companies in the Biotechnology industry, placing it in the top 14.4%.
Is Puma Biotechnology's Days Inventory too high?
Puma Biotechnology's current Days Inventory of 62.19 is 84% above median its 10-year median of 33.79. Over the past 10 years, this metric has ranged from a low of 24.53 to a high of 132.91. The Biotechnology industry median Days Inventory is 182.25. Puma Biotechnology's value of 62.19 is 65.9% below this industry median. Based on the distribution chart, Puma Biotechnology ranks #92 out of 638 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Puma Biotechnology has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Puma Biotechnology's Days Inventory compare to EVMN and OCGN?
According to the Biotechnology industry distribution chart, Puma Biotechnology ranks #92 out of 638 companies for Days Inventory. This places Puma Biotechnology in the top 14% of its industry — outperforming the majority of peers. The industry median Days Inventory is 182.25. Puma Biotechnology's value of 62.19 is 65.9% below this benchmark. Historically, Puma Biotechnology's own Days Inventory has ranged from 24.53 to 132.91 over the past decade. While the company's 10-year median is 33.79 vs. the industry median of 182.25, Puma Biotechnology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 182.25, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Puma Biotechnology's current Days Inventory of 62.19 is 65.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Puma Biotechnology and its competitors. For the Biotechnology industry, the median Days Inventory is 182.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Puma Biotechnology's current Days Inventory is 62.19, which is 84% above median its own 10-year median of 33.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Puma Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Puma Biotechnology (PBYI) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.34, compared to a current price of $7.69 — trading 130.2% above its estimated fair value. The current Days Inventory is 62.19, which is 84% above median its 10-year median of 33.79 and 65.9% below the Biotechnology industry median of 182.25. Puma Biotechnology's overall GF Score™ is 53/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Puma Biotechnology (PBYI), the current Days Inventory is 62.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Puma Biotechnology (PBYI) Overvalued in 2026?
Based on GuruFocus' analysis, Puma Biotechnology stock appears to be overvalued.
The current stock price of $7.69 is trading 130.2% above its estimated GF Value™ of $3.34.
GuruFocus considers Puma Biotechnology to be Significantly Overvalued.
Key valuation signals for PBYI:
Days Inventory: 62.19 (84% above median its 10-year median of 33.79)
GF Value™: $3.34 vs. price of $7.69 (130.2% above fair value)
Industry Position: 65.9% below the Biotechnology median (#92 of 638)
No single metric tells the full story. See the PBYI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
53GF Score
Get the complete analysis for PBYI
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBYI has been successfully added to your 
